Anti-VEGF/Ang-2 Therapy: A Promising Advance for Faster Drying in Diabetic Macular Edema (DME)

LAS VEGAS — A VEGF/Ang-2 inhibitor demonstrated faster drying compared with faricimab in patients with diabetic macular edema, according to a study presented at Clinical Trials at the Summit.
Margaret Chang, MD, MS, of Retinal Consultants Medical Group in Sacramento, California, presented results from the JADE proof-of-concept trial, which compared OLN324 (Ollin Biosciences) vs. Vabysmo (faricimab, Genentech) in patients with DME.
The trial included 83 patients with DME who were either treatment naive or previously treated. Patients were divided into three groups: OLN324 2 mg (27…

Main Article: A Glimpse into Enhanced DME Management

The recent presentation by Dr. Margaret Chang at Clinical Trials at the Summit has brought exciting news for the ophthalmology community, particularly for those managing Diabetic Macular Edema (DME). The JADE proof-of-concept trial unveiled preliminary data suggesting that OLN324, a novel anti-VEGF/Ang-2 inhibitor from Ollin Biosciences, may offer a significant advantage: faster resolution of macular fluid compared to faricimab (Vabysmo) in DME patients.

Faster drying of the macula is a critical clinical endpoint in DME treatment. Macular edema, characterized by fluid accumulation, distorts retinal architecture and is a primary driver of vision loss in diabetic patients. Rapid and sustained fluid resolution is generally associated with better visual outcomes and can potentially reduce the frequency of intravitreal injections over time, thereby alleviating treatment burden for both patients and healthcare systems. While faricimab, also a dual anti-VEGF/Ang-2 inhibitor, has already improved treatment paradigms with its extended durability, the prospect of an agent that achieves even faster drying is highly compelling. It suggests that different molecular approaches to inhibiting these key angiogenic pathways could yield distinct clinical benefits.

It is important to emphasize that the JADE trial is a proof-of-concept study involving 83 patients, a relatively small cohort. As such, these findings, while encouraging, are preliminary. They lay the groundwork for larger, pivotal Phase 3 trials that will be essential to fully evaluate OLN324’s efficacy, long-term safety, durability, and its precise role within the evolving landscape of DME therapies. Nonetheless, this early data signals a potential for further optimization in treating this complex, sight-threatening condition.

Background: Understanding DME and Current Therapeutic Approaches

Diabetic Macular Edema (DME) is a severe complication of diabetes, posing a significant threat to central vision. It arises from the breakdown of the blood-retinal barrier due to chronic hyperglycemia, leading to leakage of fluid and plasma components into the macula—the part of the retina responsible for sharp, detailed vision. This fluid accumulation causes swelling, distorting the macula and resulting in blurred vision, impaired color perception, and difficulty with tasks requiring fine visual acuity.

The pathogenesis of DME is multifactorial, but two key molecular pathways have emerged as central targets for therapy: Vascular Endothelial Growth Factor (VEGF) and Angiopoietin-2 (Ang-2). VEGF is a potent pro-angiogenic and pro-permeability factor. It directly promotes the formation of leaky blood vessels and increases vascular permeability, driving fluid leakage into the retina. Angiopoietin-2, on the other hand, acts in concert with VEGF. It destabilizes existing blood vessels, making them more susceptible to VEGF’s effects, and contributes to inflammation. A balanced interplay with Angiopoietin-1 (Ang-1) is crucial for vascular stability; Ang-2 shifts this balance towards permeability and vessel destabilization.

For years, the cornerstone of DME treatment has been anti-VEGF monotherapy with agents like ranibizumab, aflibercept, and off-label bevacizumab. These therapies have revolutionized the management of DME, significantly reducing fluid and improving visual acuity in many patients. However, some individuals show an incomplete response or require frequent injections to maintain gains, highlighting an unmet need.

Recognizing the synergistic roles of VEGF and Ang-2, pharmaceutical innovation led to the development of faricimab (Vabysmo), the first bispecific antibody designed to inhibit both VEGF-A and Ang-2. Faricimab’s introduction provided a more comprehensive blockade of the pathways implicated in DME pathogenesis, often allowing for extended treatment intervals in suitable patients. The emergence of OLN324, another dual anti-VEGF/Ang-2 inhibitor, suggests continued exploration into how best to target these crucial pathways, potentially leading to even more potent or rapid responses in reducing macular fluid.

Why This Matters for Patients and Practitioners

The preliminary data from the JADE trial, indicating faster drying with OLN324 compared to faricimab, holds considerable promise for both patients living with DME and the ophthalmologists who treat them. Here’s why this advancement matters:

1. Improved Patient Outcomes: Faster resolution of macular fluid directly correlates with quicker visual improvement. For patients, this could mean regaining functional vision more rapidly, which significantly impacts their quality of life, independence, and ability to perform daily activities. While visual acuity data would be crucial for confirmation in larger trials, reducing fluid quickly is a strong indicator of potential visual benefit.
2. Addressing Unmet Needs: Despite the efficacy of existing anti-VEGF therapies, a subset of DME patients remains suboptimally responsive or requires very frequent injections to control their disease. A therapy that offers superior or faster drying could be a game-changer for these individuals, providing a new option where current treatments fall short.
3. Enhanced Treatment Efficiency: While the JADE trial’s primary finding is faster drying, a more rapid initial response might translate into the potential for longer treatment intervals in the maintenance phase or fewer overall injections over a patient’s treatment course. This reduces the burden on patients (fewer clinic visits, less discomfort) and the healthcare system.
4. Reinforcing Multi-Pathway Inhibition: This study further validates the strategy of targeting multiple pathways (VEGF and Ang-2) in complex retinal diseases like DME. It underscores that optimal therapeutic outcomes might be achieved by simultaneously addressing the various molecular drivers of vascular leakage and inflammation.
5. Fueling Future Research and Innovation: The success of a proof-of-concept trial like JADE stimulates further research and development in this field. It encourages the scientific community to explore different molecules and delivery systems that can enhance efficacy and safety for retinal conditions. The competition among novel therapies ultimately benefits patients by driving continuous improvement in care standards.

While we await the results of larger, more definitive clinical trials, these early findings regarding OLN324 are a beacon of hope. They suggest that we are continually refining our ability to combat diabetic macular edema, moving closer to a future where vision loss from diabetes can be more effectively prevented and even reversed. As retina specialists, we remain eager to see how these innovations will shape our clinical practice and, most importantly, improve the lives of our patients.